Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

  • Butrón-Bris, B.
  • Llamas-Velasco, Mar|||0000-0002-1187-1341
  • Ovejero-Benito, M.C.
  • Santos-Juanes, Jorge|||0000-0001-5578-3522
  • Martínez-López, A.
  • Ruíz Villaverde, Ricardo|||0000-0002-0381-6174
  • Roustan, G.
  • Baniandrés Rodríguez, Ofelia|||0000-0001-8183-3941
  • Izu, Rosa Maria
  • De la Cueva, Pablo|||0000-0003-4807-3551
  • Sahuquillo-Torralba, A.
  • González Quesada, Alicia
  • Vilarrasa-Rull, Eva|||0000-0001-6507-0534
  • Pujol-Montcusí, J.
  • García-Martínez, J.
  • Navares, M.
  • Palomar-Moreno, I.
  • Novalbos, J.
  • Abad-Santos, Francisco|||0000-0002-6519-8885
  • Daudén, E.
  • Fuente, Hortensia de la
Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from-Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR <0.15 were included in a multiple regression model. Sixty three percent of patients achieved an absolute PASI ≤1 at 6 months, while 71% did so after 12 months. Disease duration (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dyadic Ru-based nanomaterials for visible light-driven photocatalytic hydrogen evolution

  • Martí Balaguer, Gerard|||0000-0002-5888-6671
  • Alique, Marc|||0000-0001-8482-5111
  • López, Isidoro|||0000-0002-6014-0078
  • Francàs, Laia|||0000-0001-9171-6247
  • Bofill, Roger|||0000-0002-8888-1871
  • Schott, Oliver|||0000-0003-4780-9037
  • Hanan, Garry S.
  • Lozano Roche, Álvaro|||0000-0002-8970-4375
  • Romero Fernández, Nuria|||0000-0002-2704-7779
  • Philippot, Karine|||0000-0002-8965-825X
  • Llobet Dalmases, Antoni|||0000-0002-6176-5272
  • Natali, Mirco|||0000-0002-6638-978X
  • García-Antón, Jordi|||0000-0002-2401-0401
  • Sala, Xavier|||0000-0002-7779-6313
Visible light-driven water splitting is an appealing strategy to store renewable energy in the chemical bonds of molecular hydrogen. In this regard, the development of photocatalytic architectures where charge transfer and recombination can be controlled represents a key challenge. The surface functionalization of Ru/RuO nanoparticles (NPs) with the [Ru(2,2'-bpy)(qpy)](PF) photosensitizer (PS), yielding PS-NPs "dyadic" hybrid nanomaterials, represents a promising strategy. Four HER photocatalysts with different PS:NPs ratios are synthesized and thoroughly characterized by analytical and spectroscopic techniques. X-ray photoelectron spectroscopy (XPS) reveals the covalent binding of the PS to the NPs surface. Analysis of the photocatalytic performance in aqueous triethanolamine (TEOA) shows that the activation of the nanocatalyst (RuO reduction) and the hydrogen evolution rate improves when the PS loading increases. Under visible-light irradiation, the nanomaterials with higher PS loading show sustained production of hydrogen for at least 80 h. The morphological and compositional evolution of the hybrid nanomaterials under photocatalytic conditions is studied and correlated with hydrogen production rates over time, pointing to a sequential leaching of PS from the nanomaterials surface. Additionally, photophysical experiments allow attaining an insight into the photochemical mechanism, which involves oxidative quenching with a fast electron injection, but also fast back electron transfer.
Repisalud
Publication Artículo científico (JournalArticle)

Unraveling CD69 signaling pathways, ligands and laterally associated molecules.

  • Jiménez-Fernández, María
  • de la Fuente, Hortensia
  • Martín, Pilar
  • Cibrián, Danay
  • Sánchez-Madrid, Francisco
CD69 is an early leukocyte activation marker involved in the regulation of the immune response. Initial studies evaluated its function using monoclonal antibodies until knock-out mice were developed. Subsequently, four ligands for CD69 have been identified, namely galectin-1, S100A8/S100A9 complex, myosin light chains 9 and 12, and oxidized low-density lipoproteins. In addition, several molecules are laterally associated with and regulated by CD69, including calreticulin and two transmembrane receptors, sphingosine-1-phosphate receptor (S1P1) and the heterodimeric amino acid transporter complex SLC7A5-SLC3A2 (LAT1-CD98). Recently, CD69 engagement has been shown to induce the expression of the immunoregulatory receptor programmed cell death-1 (PD-1) in T cells. The molecular signaling induced by CD69 has been explored in different scenarios and cell types. This review provides a perspective on the molecular pathways, ligands and cellular functions known to be regulated by CD69.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

VIP/VPAC Axis expression in immune-mediated inflammatory disorders: associated miRNA signatures

  • Lamana Domínguez, Amalia
  • Castro Vázquez, David
  • Fuente Flores, Hortensia de la
  • Triguero Martínez, Ana
  • Martínez Hernández, Rebeca
  • Revenga Martínez, Marcelino
  • Villanueva Romero, Raúl
  • Llamas Velasco, Mar
  • Chicharro Manso, Pablo
  • Juarranz Moratilla, Yasmina
  • Marazuela Aspiroz, Mónica
  • Sales Sanz, Marco
  • García de Vicuña Pinedo, María del Rosario
  • Tomero Muriel, Eva Gloria
  • González Alvaro, Isidoro
  • Martínez Mora, María del Carmen
  • Pérez Gomáriz, Rosa María
17 p., Few studies have considered immune-mediated inflammatory disorders (IMID) together, which is necessary to adequately understand them given they share common mechanisms. Our goal was to investigate the expression of vasoactive intestinal peptide (VIP) and its receptors VPAC1 and VPAC2 in selected IMID, analyze the effect of biological therapies on them, and identify miRNA signatures associated with their expression. Serum VIP levels and mRNA of VPAC and miRNA expression in peripheral blood mononuclear cells were analyzed from 52 patients with psoriasis, rheumatoid arthritis, Graves' disease, or spondyloarthritis and from 38 healthy subjects. IMID patients showed higher levels of VIP and increased expression of VPAC2 compared to controls (p < 0.0001 and p < 0.0192, respectively). Receiver operating characteristic curve analysis showed that the levels of VIP or VPAC2 expression were adequate discriminators capable of identifying IMID. Treatment of IMID patients with anti-TNFα and anti-IL12/23 significantly affected serum VIP levels. We identified miRNA signatures associated with levels of serum VIP and VPAC2 expression, which correlated with IMID diagnosis of the patients. The results indicate that the expression of VIP/VPAC2 is able of identify IMIDs and open up a line of research based on the association between the VIP/VPAC axis and miRNA signatures in immune-mediated diseases., Ministerio de Economía y Competitividad, Fondo Europeo de Desarrollo Regional (FEDER), Comunidad de Madrid